Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its 2022 Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Québec. The detailed results of the votes received by proxy are as follows:

Election of Directors

Director Nominees	NUMBER OF SHARES		PERCENTAGE OF VOTES CAST
	FOR	WITHHELD	FOR	WITHHELD
Daniel N. Chicoine	4,616,653	148,815	96.9%	3.1%
David A. Copeland	4,378,536	386,932	91.9%	8.1%
Anthony E. Dobranowski	4,363,268	402,200	91.6%	8.4%
John C. London	4,375,612	389,856	91.8%	8.2%
Thomas Schlader	4,692,345	73,123	98.5%	1.5%
Deborah Shannon-Trudeau	4,705,132	60,336	98.7%	1.3%

Appointment of External Auditors

Outcome	NUMBER OF SHARES		PERCENTAGE OF VOTES CAST
	FOR	WITHHELD	FOR	WITHHELD
Ernst & Young LLP reappointed	5,442,357	15,130	99.7%	0.3%

Approval of the Continuation of Crescita’s Shareholder Rights Plan

Outcome	NUMBER OF SHARES		PERCENTAGE OF VOTES CAST
	FOR	AGAINST	FOR	AGAINST
Shareholder Rights Plan approved	4,648,487	116,981	97.5%	2.5%

About Crescita Therapeutics Inc.
Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and early to commercial stage prescription products. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. For further details, visit www.crescitatherapeutics.com.